From Receiving to Release: Why Biodecontamination Must Function as a System
Contamination control in pharmaceutical manufacturing—and increasingly in animal research and public health laboratory environments—is no longer evaluated step-by-step. Under Annex 1 expectations, it is assessed as a facility-wide, documented, and repeatable system.
That shift is subtle—but operationally significant.
Because while many facilities still apply biodecontamination at key points, contamination risk is not limited to isolated steps. It exists across transitions—as materials move from receiving to preparation, through material airlocks, into cleanrooms, isolators, biosafety cabinets (BSCs), vivariums, and containment laboratories, and ultimately to fill-finish and release.
And each of those transitions introduces variability.
The Hidden Risk: Transitions, Not Just Spaces
Most contamination control strategies are designed around spaces:
- Cleanrooms
- Isolators
- Biosafety cabinets (BSCs)
- Vivarium and BSL environments
But in practice, risk is often introduced between those spaces.
Every time materials:
- Enter a facility
- Move through a material airlock
- Transfer into higher classification or containment areas
- Interact with equipment or enclosures
…the contamination control state changes.
This is especially relevant in environments such as BSL laboratories and vivariums, where material movement, personnel flow, and containment boundaries create additional transition points.
These transitions are where:
- Manual processes vary
- Coverage may be inconsistent
- Documentation becomes fragmented
In other words:
Every transition introduces risk. Every transition requires control.
Why Step-Based Biodecontamination Falls Short
Applying biodecontamination as a series of independent steps creates challenges:
- Inconsistent execution across operators and shifts
- Gaps in coverage between environments
- Limited integration with facility systems
- Fragmented data and documentation
This is particularly true in environments where manual processes span multiple rooms, enclosures, or containment zones.
Even when individual steps are validated, the overall process may not be consistently controlled.
And under Annex 1—and broader contamination control expectations—consistency and traceability matter just as much as efficacy.
A Shift in Thinking: From Application to System
To address this, biodecontamination needs to be considered not as a task—but as a connected system applied across the process.
This means:
- Coverage designed across environments—not assumed
- Cycles that are repeatable and controlled
- Integration with facility systems (e.g., BAS)
- Data that is captured, stored, and reviewable
At a practical level, this shifts biodecontamination from:
- Manual execution → engineered control
- Isolated steps → coordinated processes
What an Integrated Biodecontamination Strategy Looks Like
An integrated approach does not require every facility to adopt full “lights-out” operation.
Instead, it creates a scalable framework that can support:
- Targeted biodecontamination in high-risk areas
- Automated cycles for material transfer and cleanroom applications
- Integrated systems for isolators, biosafety cabinets, and containment environments
- Facility-level coordination through building systems
The common thread is not the level of automation—it’s the consistency of control.
Effective systems are designed to deliver:
- Repeatable, controlled cycles
- Validated performance
- Integration across environments and processes
- Operational efficiency and throughput support
The Role of Chemistry and Delivery
Achieving this level of control also depends on how biodecontamination is delivered.
Systems using vaporized hydrogen peroxide must balance:
- Efficacy
- Material compatibility
- Cycle time
- Safety
Lower concentration approaches, when properly engineered and validated, can support effective sporicidal performance while reducing material impact and improving cycle efficiency.
Material compatibility considerations are particularly important in laboratory and vivarium environments, where sensitive equipment, enclosures, and surfaces must be protected.
Equally important is how vapor is distributed:
- Engineered nozzle systems for larger spaces
- Targeted delivery for smaller enclosures
- Integrated approaches for isolators, BSCs, and equipment
Coverage is not incidental—it must be designed.
From Standalone Tools to Integrated Systems
As facilities evaluate their contamination control strategy, a key realization is emerging:
This level of control cannot be achieved with standalone tools alone.
It requires a system approach—one that connects:
- Equipment
- Spaces
- Transfer points
- Data
And aligns them with the facility’s contamination control strategy.
A Practical Path Forward
Not every facility will implement full automation across all processes—and that’s not required.
What matters is aligning your biodecontamination approach with:
- Your risk assessment
- Your process flow
- Your operational constraints
For some, that may mean improving consistency in targeted applications.
For others, it may involve integrating biodecontamination into material transfer, cleanroom, or containment workflows.
And for some, it may extend to fully automated, facility-wide systems.
The goal is not uniformity—it is control, consistency, and confidence.
This system-level approach is increasingly relevant across biopharmaceutical manufacturing, animal research facilities, and public health laboratories.
Where CURIS System Fits
CURIS System supports this transition by enabling integrated, scalable biodecontamination strategies across the full process—from receiving to release, as well as within research, containment, and vivarium environments.
With engineered vapor delivery, automated and repeatable cycles, and integration with facility systems, CURIS solutions are designed to help you apply the right level of control where it matters most.
👉 Explore how integrated biodecontamination systems can be implemented in your facility.
Frequently Asked Questions
Q: Does an integrated biodecontamination strategy require full automation?
A: No. Integrated approaches can range from targeted applications to fully automated systems, depending on facility needs, risk assessment, and operational goals.
Q: How does this align with Annex 1 expectations?
A: Annex 1 emphasizes consistency, repeatability, and documentation across contamination control processes. Integrated systems help support these requirements by reducing variability and improving traceability.
Q: Can this approach be applied outside pharmaceutical manufacturing?
A: Yes. The same system-level principles apply to animal research facilities, vivariums, and public health laboratories where contamination control spans multiple environments and transitions.